Mednet Logo
HomeRadiation Oncology
Radiation Oncology

Radiation Oncology

Expert insights on radiation treatment planning, techniques, toxicity management, and multimodal cancer care.

Recent Discussions

How do you sequence radiation and capecitabine in breast cancer patients receiving adjuvant capecitabine for residual disease after neoadjuvant chemotherapy?

21
6 Answers

Mednet Member
Mednet Member
Radiation Oncology · Mayo Clinic, Rochester, MN

According to personal communication with Dr. Masakazu Toi (June 13, 2017), the corresponding author of the CREATE-X NEJM publication, radiotherapy was administered prior to capecitabine in the majority of cases on this study. It is worth noting that in CALGB 49907, a randomized trial comparing capec...

How long after achieving a CR would you consider stopping pembrolizumab in metastatic melanoma?

1 Answers

Mednet Member
Mednet Member
Medical Oncology · Institut Gustave Roussy

Based on Keynote 001 and more recently on Keynote 006, where we observed sustained remission in more than 90% of the patients who had stopped pembrolizumab for complete response, we usually consider stopping pembrolizumab in patients who have a confirmed complete response (this means that we have tw...

How long can you delay the start of radiation in a patient who has received adjuvant chemotherapy after lumpectomy/mastectomy?

1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Rutgers Robert Wood Johnson Medical School

I generally start radiation between 3 and 8 weeks following the last dose of chemotherapy. Since most protocol guidelines specify radiation should start within 12 weeks of the last day of chemo is within the last surgical procedure, I use that as an outside window I am comfortable with for the most ...

Do you recommend chemoradiation following neoadjuvant FOLFIRINOX for resectable pancreatic cancer?

1
4 Answers

Mednet Member
Mednet Member
Medical Oncology · University of Wisconsin

Tough question, with lots of evolution in this area in the past few years. The data would suggest that for borderline resectable pancreatic cancer, there is a benefit in terms of OS from preoperative treatment. For unresectable disease, the small chance of conversion into resectability is worth the ...

When should you use single-fraction radiotherapy for spinal cord compression?

14
5 Answers

Mednet Member
Mednet Member
Radiation Oncology · Rochester Regional Health Aco Inc

The SCORAD III trial is practice changing. But I do NOT plan to treat ALL patients with spinal cord compression with a single fraction of 8 Gy now. Here is why: SCORAD III is extremely important new study for the management of metastatic epidural spinal cord compression (MESCC) for patients with sho...

How would you manage a patient with recurrent, high-grade leiomyosarcoma involving the pelvis after salvage exenteration but has a focally positive anterior margin? She has previously had pelvic radiation 2 years ago.

1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Harold C Simmons Comprehensive Cancer Center/UT Southwestern

Ideally plan for intraoperative radiation or surface Brachytherapy at time of surgery

How do you follow patients after SBRT for NSCLC?

5
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Cleveland Clinic

When we started our lung SBRT practice almost 13 years ago, the follow up schedule was based on trying to measure the benefits and impact of the therapy in a fairly structured fashion so that we could develop expertise in understanding outcomes, radiographic changes, patient experience, and treatmen...

Are CHEK2 mutations a contraindication for breast conservation therapy with lumpectomy + RT?

3
4 Answers

Mednet Member
Mednet Member
Medical Oncology · Columbia University Medical Center

Among women with early-stage breast cancer and moderate penetrance breast cancer susceptibility genes, such as CHEK2, decisions about breast surgery are largely based upon personal preferences. According to data from large population-based studies, women with CHEK2 pathogenic variants have about a 2...

Do you use either memantine or hippocampal sparing technique to preserve cognitive function when giving whole brain radiotherapy?

4
7 Answers

Mednet Member
Mednet Member
Radiation Oncology · Mayo Clinic

Dr. @Dr. First Last and I put together the response below:We use memantine and hippocampal sparing technique for all brain metastasis patients who are planning to receive WBRT. This is based off the recently published phase III trial NRG CC001 that found hippocampal avoidance WBRT plus memantine res...

What factors do you consider when selecting dose/fractionation for whole brain radiotherapy?

1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Columbia University Irving Medical Center

I assume this question is for brain metastases patients who are not eligible for hippocampal avoidance WBRT (ineligible criteria including but not limited to - mets 5 mm within either hippocampus, germ cell/small cell/lymphoma, leptomeningeal disease, etc.) - my default WBRT dose fractionation is 30...